Table 11.
Awareness and knowledge survey response comparisons.
| Awareness | 1. Ireland | 2. Western Australia [2014 (20)] | 3. Cardiac HCPs Victoria, Australia 2019 (24) | 4. Australia [2017–(21)] | 5. Japan | 6. Malaysia | 7. South Korea | 8. Philippines | 9. Hong Kong | 10. China | 11. Vietnam | 12. Taiwan | 13. UK (25) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Familiarity of FH rated as above average (>4) (personal) | 5% | 32% | 23% | 38% | 28% | 34% | 50% | 23% | 49% | 47% | 39% | ||
| Familiarity of FH rated as average (3) (personal) | 65% | 62% (average or above) | 76% | ||||||||||
| Awareness about FH guidelines | 70% | 33% | 43% | 36% | 47% | 35% | 34% | N/A | 43% | 8% | 28% | 53% | 61% |
| Awareness about lipid specialists | 55% | 62% | 36% | 51% | 33% | 34% | 30% | 31% | 40% | 12% | 39% | 57% | 50% |
| Knowledge | |||||||||||||
| Correctly described FH | 95% | 80% | 63% | 72% | 77% | 86% | 51% | 73% | 62% | 75% | 65% | 60% | 89% |
| Correctly identified lipid profile | 70% | 68% | 68% | 59% | 85% | 65% | 57% | 48% | 51% | 85% | 45% | 61% | 74% |
| Correctly identified prevalence of FH in the community | 45% | 27% | 16% | 26% | 41% | 24% | 19% | 16% | 11% | 17% | 14% | 30% | 30% |
| Correctly identified the transmission rate of FH to first-degree relatives | 65% | 45% | 44% | 40% | 49% | 42% | 37% | 49% | 36% | 26% | 61% | 51% | |
| Correctly identified the cardiovascular disease risk in untreated FH patients | 45% | 29% | 48% | 14% | 13% | 9% | 8% | 10% | 7% | 4% | 2% | 5% | 14% |
| Correctly identified that genetic testing was not required to accurately diagnose FH | 35% | 50% | 50% | 52% | 47% | 64% | 68% | 38% | 38% | 58% | 24% | 52% | |
| Selected statins to best treat hypercholesterolemia | 100% | 95% | 89% | 85% | 96% | 90% | 95% | 93% | 95% | 75% | 95% | 94% | |
| Selected a combination of statin and ezetimibe to treat severe hypercholesterolemia | 65% | 74% | 64% | 48% | 56% | 70% | 48% | 49% | 77% | 31% | 63% | 50% | |
| Practice | |||||||||||||
| Screened patients with premature CAD for family history | 100% | 56% | 45% | 93% | 83% | 95% | 89% | 92% | 95% | 94% | 85% | 95% | 90% |
| Performed/referred for routine family screening of patients with FH (if GP has FH patients under their care) | 45% | 53% | 8% | 86% | 30% | 82% | 50% | 53% | 90% | 47% | 83% | 77% | 73% |
| The most prevalent age for screening young people in a family with FH was 13–18 years, which was selected by | 40% | 52% | 43% | 52% | 18% | 52% | 54% | 52% | 48% | 16% | 33% | 20% | 45% |
| Have referred FH patients to a lipid specialist (if aware of lipid specialist) | 45% | 27% | 66% | 26% | 52% | 57% | 32% | 86% | 86% | 49% | 100% | 72% | |
| Opinions on detection | |||||||||||||
| Selected GPs as the most effective healthcare provider for the early detection of FH | 75% | 84% | 72% | 80% | 45% | 92% | 71% | 58% | 76% | 8% | 23% | 50% | 82% |